Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia
The primary objective of this study is to evaluate the progression-free survival in
 participants with previously untreated chronic lymphocytic leukemia (CLL) who would otherwise
 be suitable for bendamustine and rituximab treatment as standard of care.

 An increased rate of deaths and serious adverse events (SAEs) among participants with
 front-line CLL and early-line indolent non-Hodgkin lymphoma (iNHL) treated with idelalisib in
 combination with standard therapies was observed by the independent data monitoring committee
 (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data
 and terminated this study in agreement with the DMC recommendation and in consultation with
 the US Food and Drug Administration (FDA).
Key Inclusion Criteria:

 -  Documented diagnosis of B-cell CLL, with diagnosis established according to
 International Workshop on Chronic Lymphocytic Leukemia (IWCLL)

 -  No prior therapy for CLL other than corticosteroids for disease complications

 -  CLL that warrants treatment

 -  Presence of measurable lymphadenopathy

 -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

 Key Exclusion Criteria:

 -  Known histological transformation from CLL to an aggressive lymphoma (ie, Richter
 transformation)

 -  Known presence of myelodysplastic syndrome

 -  Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of
 randomization

 -  Ongoing liver injury

 -  History of non-infectious pneumonitis

 -  Ongoing inflammatory bowel disease

 -  History of prior allogeneic bone marrow progenitor cell or solid organ transplantation

 -  Ongoing immunosuppressive therapy other than corticosteroids

 -  Received last dose of study drug on another therapeutic clinical trial within 30 days
 prior to randomization

 Note: Other protocol defined Inclusion/Exclusion criteria may apply.